Latest News

MichBio Invites MMS Founder and Chief Scientific Officer Dr. Uma Sharma to Join Board of Directors

CANTON, Mich. (August 28, 2020)– MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today that Uma Sharma, Ph.D., Founder and Chief Scientific Officer of MMS, has been invited to join the board of directors with MichBio – a trade association committed to driving growth in Michigan’s biosciences industry and its many sectors for more than 20 years. Dr. Sharma will serve on the board from August 2020 to December 2021.

Uma will represent MMS alongside other local bioscience industry leaders, including peers from Neogen, Wayne State University, University of Michigan, Emergent BioSolutions, Medbio, the Michigan Economic Development Corporation (MEDC), and several others.

“It is a pleasure for me to join a board where we can further the excellence and integrity of the pharmaceutical, biotech, and medical device industries in Michigan and across the world,” says Dr. Sharma. “Our goal is to improve the lives of people globally through strong science, innovative technology, and a sense of urgency, and I look forward to bringing this same line of advanced thinking to my duties as part of the MichBio board.”

In this role, Uma will lend her expertise and guidance to MichBio as they continue to effectively promote and advance the common goals and concerns of Michigan’s bio-industry. According to MichBio, there are currently more than 40,000 people and 1,700 bio-industry companies in Michigan that help change, improve, and save lives.

“The goal of MichBio is to help the Michigan bioscience sector define the future, and Dr. Uma Sharma and her global team of experts at MMS play a strong role in that,” says Stephen Rapundalo, Ph.D., President & CEO, MichBio, “With her expansive background, success, and knowledge in the industry, the board is elated to welcome Uma. She is a consistent leader and uniquely positioned to understand the challenges that today’s biotech and research industries face.  I know her insights will help us to promote the Michbio goals forward.”

In 2019, Dbusiness Magazine recognized Uma as a Champion of the New Economy. To learn more about MMS leadership in the pharmaceutical industry, go here: Executive leadership

About MMS Holdings

MMS is an award-winning, data and technologies-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating and was named as the Best Global Biotech CRO in the 2018 International Life Sciences Awards and Most Outstanding CRO in the 2019 Biotechnology Awards.

For more information, visit www.mmsholdings.com or follow MMS on LinkedIn.

About Michbio

Our mission encompasses broad industry sub-sector representation including pharmaceuticals and therapeutics (human and animal health, generics and OTCs), medical devices, diagnostics, research tools, informatics (healthcare and bio-informatics), nutritional health (nutriceuticals), clinical research, industrial biotechnology, and bio-fuels and bio-agriculture.

For more information, visit www.michbio.org.

Suggested For You

news

March 6th, 2024

MMS Holdings Inc – A Data-Centric CRO Powerhouse Reshaping Drug Development on a Global Scale

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

June 27th, 2022

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration Between MAPS PBC and MMS Holdings

news

May 5th, 2020

Green Valley Pharmaceutical And MMS Holdings Collaborate to Gain FDA Approval To Begin Clinical Trial For The First Alzheimer's Drug In 17 Years

news

March 20th, 2020

MMS Announces One Million Dollar Award For Pharmaceutical Companies Developing A Vaccine For COVID-19

news

May 23rd, 2019

Dr. Mike Poole Joins the Board of Scientific Advisors at Top Global CRO MMS Holdings

news

November 8th, 2018

Vivozon’s Non-Opioid Pain Killer has been granted the FDA’s Fast Track Designation through Regulatory Strategy Support from MMS

news

June 7th, 2017

Emmaus Medical’s New Drug Application for Sickle Cell Disease Recommended for Approval by FDA

news

March 14th, 2016

MMS Funds $1 Million Zika Vaccine Development Award

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

webinar

June 26th, 2024

A Psychedelic Shift: Assessing the Potential for Nonmedical Use in a Changing Regulatory Landscape

perspectives

May 21st, 2024

Psychedelics and Regulatory Considerations Part II: A Shift in Lexicon and Implications of “Nonmedical Use” On Labelling